Cerenome (CNSY) Registration filing summary
Event summary combining transcript, slides, and related documents.
Registration filing summary
5 Jun, 2026Management team and governance
Principal executive offices located in Houston, Texas, with Andrew Sims as CFO and Marc H. Hedrick, M.D. as President and CEO.
Board includes Richard J. Hawkins (Chairman), An van Es-Johansson, Howard Clowes, Kyle Guse, and Ronald A. Andrews.
Registration statement signed by executive officers and directors as of June 5, 2026.
Offering details and pricing
Registration statement filed as a pre-effective amendment to Form S-3, allowing for delayed or continuous offerings under Rule 415.
Securities may be offered from time to time after the effective date.
Equity Distribution Agreement with Canaccord Genuity LLC dated June 1, 2026.
Underwriters and syndicate
Canaccord Genuity LLC is named as the counterparty in the Equity Distribution Agreement.
Latest events from Cerenome
- Q2 2026 marked rebranding, clinical progress, and a $9.0M net loss amid capital constraints.CNSY
Q2 2026 - Cerenome rebrands and advances CNS oncology with integrated therapeutics, diagnostics, and AI.CNSY
Investor update - At-the-market equity offering of up to $17.35M targets CNS cancer innovation, with dilution risk.CNSY
Registration filing - 186RNL shows safety, efficacy, and immune activation in leptomeningeal metastases.CNSY
2026 AANS Annual Scientific Meeting presentation - Net loss narrowed, cash and investments rose, and funding remains critical amid clinical and commercial progress.CNSY
Q1 2026 - All proposals, including board election and stock plan amendment, were approved by shareholders.CNSY
AGM 2026 - Key votes include director elections, auditor ratification, and executive pay approval.CNSY
Proxy filing - $15M raise funds pivotal trials, CNSide scale-up, and 2026 commercial expansion.CNSY
Business update - $15M financing and clinical progress support CNSide's 2025 launch and CNS cancer milestones.CNSY
Q4 2024